This summary describes a publication about a study called SPRINT. The SPRINT study included 50 children with neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) that could not be removed with surgery. PNs are tumors that grow along nerves and can cause various problems for children, such as pain, changes to appearance, and muscle weakness. In SPRINT, the study team wanted to learn whether a medication called selumetinib was able to shrink the PN caused by NF1 (also known as NF1-related PN), and if shrinking PNs helped relieve children of the problems caused by it. To assess how selumetinib might help, children had scans to measure the size of their PN, completed questionnaires, and had a variety of other tests done by their doctor. Their caregivers also completed questionnaires about their child. The children took selumetinib capsules twice a day on an empty stomach.This Plain Language Summary of Publication article (PLSP) from Future Oncology focuses on neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) that could not be removed with surgery. PNs are tumours that grow along nerves and can cause problems in children, such as pain, changes in appearance, and muscle weakness. Researchers in the SPRINT study wanted to assess whether a medication called selumetinib was able to shrink the PN, known as NF1-related PN, and whether shrinking the PNs could ease the problems caused by it in children.

Visit the Future Medicine using the link to read the article.

This PLSP is based on an original article called ‘Selumetinib in Children with Inoperable Plexiform Neurofibromas’ and was published in The New England Journal of Medicine.

Visit The New England Journal of Medicine site using the link to read the article.